1. Home
  2. SACH vs CELU Comparison

SACH vs CELU Comparison

Compare SACH & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SACH
  • CELU
  • Stock Information
  • Founded
  • SACH 2010
  • CELU 2016
  • Country
  • SACH United States
  • CELU United States
  • Employees
  • SACH N/A
  • CELU N/A
  • Industry
  • SACH Real Estate Investment Trusts
  • CELU Biotechnology: Pharmaceutical Preparations
  • Sector
  • SACH Real Estate
  • CELU Health Care
  • Exchange
  • SACH Nasdaq
  • CELU Nasdaq
  • Market Cap
  • SACH 54.4M
  • CELU 56.9M
  • IPO Year
  • SACH 2017
  • CELU N/A
  • Fundamental
  • Price
  • SACH $1.07
  • CELU $1.98
  • Analyst Decision
  • SACH Hold
  • CELU Strong Buy
  • Analyst Count
  • SACH 4
  • CELU 1
  • Target Price
  • SACH $2.00
  • CELU $6.00
  • AVG Volume (30 Days)
  • SACH 207.5K
  • CELU 224.7K
  • Earning Date
  • SACH 11-13-2025
  • CELU 12-05-2025
  • Dividend Yield
  • SACH 19.05%
  • CELU N/A
  • EPS Growth
  • SACH N/A
  • CELU N/A
  • EPS
  • SACH N/A
  • CELU N/A
  • Revenue
  • SACH N/A
  • CELU $44,590,000.00
  • Revenue This Year
  • SACH N/A
  • CELU N/A
  • Revenue Next Year
  • SACH $6.63
  • CELU $76.00
  • P/E Ratio
  • SACH N/A
  • CELU N/A
  • Revenue Growth
  • SACH N/A
  • CELU 4.45
  • 52 Week Low
  • SACH $0.80
  • CELU $1.00
  • 52 Week High
  • SACH $2.51
  • CELU $5.22
  • Technical
  • Relative Strength Index (RSI)
  • SACH 40.98
  • CELU 39.59
  • Support Level
  • SACH $1.06
  • CELU $1.99
  • Resistance Level
  • SACH $1.15
  • CELU $2.35
  • Average True Range (ATR)
  • SACH 0.05
  • CELU 0.16
  • MACD
  • SACH -0.00
  • CELU 0.03
  • Stochastic Oscillator
  • SACH 15.46
  • CELU 7.90

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: